Clinical trials
Lenalidomide clinical trials
Below are recruiting lenalidomide clinical trials, each written for real people, not researchers. We’re tracking 141 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06664411RecruitingPhase 2
Pola-ZR2P for untreated DLBCL
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06697483Recruiting
Personalized maintenance therapy for multiple myeloma after stem cell transplant
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06782789Recruiting
Study of Tafasitamab and Lenalidomide for aggressive B-cell lymphoma
This study looks back at medical records of people with relapsed or refractory diffuse large B-cell lymphoma who received a combination of two drugs (tafasitamab and lenalidomide) through a special access program. The goal is to learn how well the treatment worked and what side effects occurred.
Bologna, BolognaAges 18 years+ - NCT06793189RecruitingPhase 2
Risk-Adapted Targeted Therapy for Untreated MZL
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Shanghai, ChinaAges 18 years+ - NCT06803693RecruitingPhase 2
New drug combo for untreated large B-cell lymphoma
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Birmingham, AlabamaAges 18 years+ - NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
AmiensAges 18–69 - NCT06932562RecruitingPhase 3
Testing linvoseltamab vs standard care for myeloma patients not eligible for transplant
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
AdelaideAges 18 years+ - NCT06952478RecruitingPhase 3
Comparing a new injectable multiple myeloma drug to Darzalex Faspro
This trial compares a new injectable medicine (CT-P44) to an approved one (Darzalex Faspro), both given with lenalidomide and dexamethasone, for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the new option works just as well.
Taipei, Beitou DistrictAges 18 years+ - NCT06974786RecruitingPhase 2
T-cell engager vs stem cell transplant for newly diagnosed myeloma
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Birmingham, AlabamaAges 19 years+ - NCT06997081RecruitingPhase 2
ERd combination for newly diagnosed multiple myeloma
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Miami, FloridaAges 18 years+ - NCT07018050RecruitingPhase 2
A study of a new combination for multiple myeloma
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
TianjinAges 18 years+ - NCT07072221Recruiting
Matching drugs trial for relapsed T-cell lymphoma
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
Suzhou, JiangsuAges 18 years+ - NCT07081022RecruitingPhase 2
Study of JS203 combination therapy for B-cell lymphoma
This trial tests a new combination treatment for a type of lymphoma (B-cell non-Hodgkin's lymphoma) that has a protein called CD20 on its cells. It may be an option if you have not received certain previous therapies and your lymphoma is measurable, to see if the combination can help control the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT07126236RecruitingPhase 2
Epcoritamab for first relapse of large B-cell lymphoma
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Zaragoza, AragonAges 18 years+ - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07477587RecruitingPhase 1
Comparing two myeloma treatments for new patients
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Springdale, ArkansasAges 18 years+ - NCT07663253Recruiting
Isatuximab with VRd for newly diagnosed multiple myeloma patients not eligible for transplant
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07210047Enrolling by invitationPhase 1/Phase 2
Study of HuL001 for multiple myeloma that has come back or not responded
This trial tests a new drug called HuL001 combined with lenalidomide and dexamethasone for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It aims to see if this combination can help when other options have failed.
TaipeiAges 18 years+ - NCT05690191Enrolling by invitation
Chidamide treatment for returning or hard-to-treat lymphoma
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
Suzhou, JiangsuAges 18 years+ - NCT03815279Enrolling by invitationPhase 2
Trial for active or high-risk smoldering myeloma treatments
This Phase 2 study tests a treatment approach for adults with active multiple myeloma (MM) or a high/intermediate-risk “smoldering” MM that hasn’t been treated yet. It may help by trying to control the disease earlier or more effectively, depending on what the trial drug(s) do.
ReykjavikAges 18 years+
Hear when a new Lenalidomide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lenalidomide?
- Yes. Clin2 currently lists 141 recruiting lenalidomide studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lenalidomide trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lenalidomide trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.